Product Pipeline

Product

Preclinical phase

Clinical phase

Clinical Trial Phase I/II
Bone graft for maxillofacial applications

develop bonusMaxillofacial bone defects require large amounts of bone graft to fill thebone gaps, improve the bone's strength and support dental implants. Different strategies are available to augment the impaired bone-regeneration process, including the ‘gold standard’ autologous bone graft, allograft transplantation, use of growth factors, osteoconductive scaffolds and synthetic bone substitutes. However, all current strategies are associated with substantial drawbacks and limitations to their use and availability. As a result, the necessity for more advanced treatment is crucial.

BonoFillTM is designed to induce and enhance bone regeneration without the risk of immune rejection and surgical failure. BonoFillTM is currently being evaluated in a clinical trial as an injectable bone graft for reconstructing maxillofacial bone gaps. 

Clinical Trial Phase I/II
Bone graft for orthopedic applications:

develop bonusThe increased aging world population possesses new orthopedic challenges and emphasizes the need for innovative approaches to repair bone lost through trauma or disease. The main challenges in the orthopedic arena include the regeneration of nonunion fractures and treating of critical-sized segmental defects. When a critical-sized bone defect develops, the body cannot heal itself, as cells require a solid platform upon which bone can be generated to unite the fracture. Moreover, it was shown that neovascularization (formation of new blood vessels) of the critical-sized bone defects is critical for successful union and repair of the bone defect. 

Autologous bone grafting is the "gold standard" for the repair of long critical-sized bone defects, but presents significant risks and undesirable side effects. BonoFillTM - a pre-shaped graft which precisely matches the shape of the bone void, was designed to "bridge the gap" in critical-sized bone defects. BonoFillTM is currently being evaluated in large animal studies using a critical-sized bone defect model. 

Preclinical Trials
Novel nanomaterials technology for tissue regeneration:

ProductPipelinellogos3The development of nanomaterials for tissue regeneration is a project jointly undertaken by Bonus BioGroup and the USA-based company, Cellora LLC. Cellora is developing nanoparticle composites for local vascularization of ischemic tissues, which enhance angiogenic activity and stimulate the body’s natural repair mechanism to promote tissue regeneration. The project is focusing on the integration of Cellora's novel nanomaterials with Bonus Biogroup's products for tissue engineering applications.


The novel technology enables the regeneration of both hard and soft tissue inside the patient’s body, allowing it to serve as a substitute in a variety of medical applications, precluding the need for external production of a cell-based graft. By integrating this technology, Bonus BioGroup will be able to develop and produce a variety of off-the-shelf products that do not require patient compatibility.

The project, supported by BIRD Foundation, is carried out in Cellora LLC in collaboration with Harvard-MIT Biomedical Engineering Center (BMEC) under the Division of Health Sciences and Technology (HST), and at the Research and Development headquarters of Bonus BioGroup in Haifa, Israel.

Bonus BioGroup is exclusively entitled to carry out any action to commercialize and market the developed shelf products worldwide.

Preclinical Trials
Large vascularized bone graft:

ProductPipelinellogos4Repair of large bone defects remains challenging, despite significant advances in tissue engineering technology. The major limitation of current solutions lies in the poor transport of essential growth factors throughout the entire volume of the new graft, particularly to its center. Many efforts are being directed towards development of an optimal scaffold that can support bone cells, provide mechanical cues and ensure sufficient oxygen, nutrients and desired stimuli throughout the graft.

Bonus BioGroup is collaborating with researchers at the Technion – Israel Institute of Technology and in the Galil Medical Center, to develop a novel scaffold consisting of large capillary networks. This platform will assist cell growth and vascularization by mimicking the structure of blood vessels within the body. This technology aims to provide efficient physiological diffusion of oxygen and nutrients throughout the bone graft and enables the regeneration of large bone deficiencies.

FOR MORE INVESTOR RELATION INFORMATION

Press Release, Announcements publication and more

Bonus BioGroup

Image

 

Terms of UsePrivacy Policy        

© 2019 Bonus BioGroup Ltd. All Rights Reserved. Designed By Netron Israel Ltd.